CA2606880A1 - Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy - Google Patents

Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy Download PDF

Info

Publication number
CA2606880A1
CA2606880A1 CA002606880A CA2606880A CA2606880A1 CA 2606880 A1 CA2606880 A1 CA 2606880A1 CA 002606880 A CA002606880 A CA 002606880A CA 2606880 A CA2606880 A CA 2606880A CA 2606880 A1 CA2606880 A1 CA 2606880A1
Authority
CA
Canada
Prior art keywords
sulodexide
patients
blood pressure
reducing agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002606880A
Other languages
English (en)
French (fr)
Inventor
Michael Weiss
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Keryx Biopharmaceuticals Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2606880A1 publication Critical patent/CA2606880A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
CA002606880A 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy Abandoned CA2606880A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US67909605P 2005-05-05 2005-05-05
US60/679,096 2005-05-05
US73697305P 2005-11-14 2005-11-14
US60/736,973 2005-11-14
PCT/US2006/017403 WO2006121853A1 (en) 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Publications (1)

Publication Number Publication Date
CA2606880A1 true CA2606880A1 (en) 2006-11-16

Family

ID=37396874

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002606880A Abandoned CA2606880A1 (en) 2005-05-05 2006-05-05 Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy

Country Status (6)

Country Link
EP (1) EP1883412A4 (de)
JP (1) JP2008540448A (de)
AU (1) AU2006244446A1 (de)
CA (1) CA2606880A1 (de)
IL (1) IL187142A0 (de)
WO (1) WO2006121853A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2008008213A (es) 2005-12-22 2008-09-03 Neurochem Int Ltd Tratamiento de trastornos renales, nefropatia diabetica y dislipidemias.
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
CN104017102B (zh) * 2014-06-19 2016-02-24 深圳市海普瑞药业股份有限公司 乙醇沉淀法从肝素副产物制备舒洛地特原料的方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1270846B (it) * 1993-05-10 1997-05-13 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.
IT1292426B1 (it) * 1997-06-27 1999-02-08 Nicox Sa Sali nitrati di ace-inibitori
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy

Also Published As

Publication number Publication date
EP1883412A1 (de) 2008-02-06
AU2006244446A1 (en) 2006-11-16
WO2006121853A1 (en) 2006-11-16
JP2008540448A (ja) 2008-11-20
IL187142A0 (en) 2008-06-05
EP1883412A4 (de) 2008-09-03

Similar Documents

Publication Publication Date Title
Gisen Group Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
Turgut et al. Potential new therapeutic agents for diabetic kidney disease
JP6337170B2 (ja) ネコの全身性疾患の予防又は治療の為のアンジオテンシンｉｉ受容体アンタゴニスト
Waanders et al. Current concepts in the management of diabetic nephropathy
Desai Hyperkalemia in patients with heart failure: incidence, prevalence, and management
Weinberg et al. The effect of high-dose angiotensin II receptor blockade beyond maximal recommended doses in reducing urinary protein excretion
CA2606880A1 (en) Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
PT1643999E (pt) Piridoxamina para utilização no tratamento de nefropatia diabética na diabetes tipo ii
Nakhoul et al. Diabetic nephropathy from RAAS to autophagy: the era for new players
Andersen et al. Angiotensin converting enzyme inhibitors and angiotensin II receptor blockers: evidence for and against the combination in the treatment of hypertension and proteinuria
Ku et al. Role of aldosterone in the progression of chronic kidney disease and potential use of aldosterone blockade in children
Mann et al. Renin-angiotensin system inhibition in the treatment of hypertension
Anantharaman et al. Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy
Bakris et al. Monitoring and managing urinary albumin excretion: practical advice for primary care clinicians
Rayner Advances in the treatment of diabetic renal disease: focus on losartan
Gilligan et al. ANGIOTENSIN-CONVERTING enzyme inhibitors and angiotensin receptor blocker
Andersen et al. Inhibition of the renin-angiotensin system, with particular reference to dual blockade treatment
Doggrell Class benefits of AT1 antagonists in Type 2 diabetes with nephropathy
Rani Drug and diabetic nephropathy
Rupp Risk reduction by preventing stroke: need for blockade of angiotensin II and catecholamines?
Saraswathi et al. Exploring Novel Therapeutic Approaches for Chronic Kidney Disease
Chambers Telmisartan an effective antihypertensive for 24-hour blood pressure control
Trojacanec et al. Effects of dual RAAS blockade with candesartan and perindopril on functional renal tests in streptozotocin induced diabetic nephropathy.
Lakkis et al. Jay Ian Lakkis and Matthew R. Weir
Johnston Angiotensin receptor antagonists for the treatment of hypertension

Legal Events

Date Code Title Description
FZDE Discontinued
FZDE Discontinued

Effective date: 20090505